GlassScriptPhysician profile
Shuja Yousuf
NPI 1881643088
$6,080.89
in general payments reported to CMS, 2019-2025
20 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $415 · 2021: $730 · 2022: $368 · 2023: $723 · 2024: $3,200 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,502 · Travel and Lodging: $1,635 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,502.30 |
| Travel and Lodging | $1,635.07 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $2,299.59 | 2024 | |
| Janssen Biotech, INC. | $810.20 | 2021-2025 | Stelara, Tremfya, Remicade |
| Abbvie INC. | $744.52 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $734.79 | 2019-2024 | Trulance, Plenvu, Xifaxan |
| Qol Medical, LLC | $317.41 | 2024-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $190.62 | 2021-2023 | |
| Boston Scientific Corporation | $167.64 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $141.56 | 2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $134.93 | 2023-2024 | Stelara |
| Celgene Corporation | $121.39 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $99.88 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.55 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $50.44 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $44.16 | 2021 | |
| Merck Sharp & Dohme LLC | $41.84 | 2022-2023 | Dificid |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $33.06 | 2021-2022 | |
| Madrigal Pharmaceuticals | $25.50 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $22.99 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $14.95 | 2021 | |
| Allergan, INC. | $13.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuja Yousuf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.